Re: "Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial" by Crippa et al.

[1]  D. Meltzer,et al.  Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. , 2022, Science advances.

[2]  Yuanting Zheng,et al.  Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients , 2022, BMC Medicine.

[3]  M. Falasca,et al.  Modulatory role of the Endocannabinoidome in the pathophysiology of the gastrointestinal tract. , 2021, Pharmacological research.

[4]  L. Vitetta,et al.  Enhancing Endocannabinoid Control of Stress with Cannabidiol , 2021, Journal of clinical medicine.

[5]  L. Vitetta,et al.  The intestinal microbiota and improving the efficacy of COVID-19 vaccinations , 2021, Journal of Functional Foods.

[6]  F. Guimarães,et al.  Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. , 2021, Cannabis and cannabinoid research.

[7]  F. Guimarães,et al.  Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic , 2021, JAMA network open.

[8]  L. Vitetta,et al.  Altered gut microbial metabolites could mediate the effects of risk factors in Covid‐19 , 2021, Reviews in medical virology.

[9]  C. Lucas,et al.  The pharmacokinetics and the pharmacodynamics of cannabinoids. , 2018, British journal of clinical pharmacology.

[10]  S. Oliaro-Bosso,et al.  Cannabinoid Delivery Systems for Pain and Inflammation Treatment , 2018, Molecules.

[11]  Jennifer H. Martin,et al.  Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling , 2018, British journal of clinical pharmacology.

[12]  M. Huestis,et al.  Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. , 2011, Clinical chemistry.

[13]  Franjo Grotenhermen,et al.  Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.